Any of the following prior therapies:* Chemotherapy =< 4 weeks prior to registration* Mitomycin C/nitrosoureas =< 6 weeks prior to registration* Immunotherapy =< 4 weeks prior to registration* Biologic therapy =< 4 weeks prior to registration* Radiation therapy =< 4 weeks prior to registration* Radiation to > 25% of bone marrow * Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) =< 4 weeks prior to registration; subjects with prostate cancer will be permitted to continue hormone therapyXx_NEWLINE_xXReceived treatment with radiation therapy or investigational therapy =< 28 days prior to registrationXx_NEWLINE_xXAny of the following prior therapies:* Chemotherapy =< 28 days prior to registration* Mitomycin C/nitrosoureas =< 42 days prior to registration* Immunotherapy =< 28 days prior to registration* Biologic therapy =< 28 days prior to registration* Radiation therapy =< 28 days prior to registration* Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA] approved indication and in the context of a research investigation) =< 28 days prior to registration* Prior poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor therapyXx_NEWLINE_xXNo other chemotherapy or radiation therapy within 14 days prior to registrationXx_NEWLINE_xXNo investigational therapy within 14 days prior to registrationXx_NEWLINE_xXPatients must not have received any prior systemic therapy (systemic chemotherapy, immunotherapy or investigational drug) within 21 days prior to sub-study registration; patients must have recovered (=< grade 1) from any side effects of prior therapy; patients must not have received any radiation therapy within 14 days prior to sub-study registrationXx_NEWLINE_xXNo treatment with chemotherapy, radiation therapy, immunotherapy, biological therapy, hormonal therapy, or other thiazolidinediones (TZDs) =< 21 days before study registrationXx_NEWLINE_xXProgression on at least one prior systemic chemotherapy for advanced, unresectable or metastatic disease; prior adjuvant or neoadjuvant therapy is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollment* There is no limit to the number of prior lines of treatment a patient has received* No treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration* Patients should have resolution of any toxic effects of prior therapy (except alopecia) to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, grade 1 or lessXx_NEWLINE_xXAny number of the following prior therapies is allowed:* Chemotherapy >= 28 days prior to registration* Mitomycin C/nitrosoureas >= 42 days prior to registration* Immunotherapy >= 28 days prior to registration* Biologic therapy >= 28 days prior to registration* Targeted therapy >= 28 days prior to registration* Radiation therapy >= 28 days prior to registration* Radiation to < 25% of bone marrowXx_NEWLINE_xXNo treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registration; for GIST, tyrosine kinase inhibitor can be continued for up to 3 days prior to initiation of study treatmentXx_NEWLINE_xXNo treatment with immunotherapy =< 21 days before re-registration; no treatment with biologic therapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before re-registration; no treatment with nitrosourea or mitomycin =< 42 days before re-registrationXx_NEWLINE_xXNo treatment with biologic therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registrationXx_NEWLINE_xXPatients must have completed any prior radiation therapy and hormonal therapy at least 14 days prior to registrationXx_NEWLINE_xXNo treatment with biological therapy, immunotherapy, chemotherapy, investigational agent for malignancy, or radiation =< 28 days before study registration; no treatment with nitrosourea or mitomycin =< 42 days before study registrationXx_NEWLINE_xXNo treatment with radiation therapy =< 28 days before study registrationXx_NEWLINE_xXPatients must have completed systemic therapy at least 14 days prior to registration, any surgical procedure must have been performed at least 14 days prior to registration, and radiation therapy must be completed at least 7 days prior to registration; patients must have recovered from major side effects of prior therapies or procedures in the opinion of the local site investigator prior to registrationXx_NEWLINE_xXPatients may have received prior therapy (including chemotherapy, biologic/targeted therapy and immunotherapy) for treatment of endometrial cancer; all therapy must be discontinued at least 4 weeks prior to registration; any investigational agent must be discontinued at least 30 days prior to registrationXx_NEWLINE_xXPatients must not have had surgery, biologic therapy, or hormonal therapy within 14 days prior to registration; patients must not have had chemotherapy, targeted small molecule therapy, or radiation therapy within 28 days (42 days for nitrosoureas or mitomycin C) prior to registration; patients must not have had an investigational agent or monoclonal antibodies, except anti-PD1/L1 antibodies, within 28 days prior to registration* Patients must have recovered from all adverse events due to prior anti-cancer therapy (residual toxicity =< grade 1) prior to registration, with the exception of patients with =< grade 2 neuropath or =< grade 2 alopecia* If patients received major surgery, they must have recovered adequately from toxicity and/or complications from the intervention prior to registrationXx_NEWLINE_xXFor all forms of systemic therapy, patients must have completed therapy at least 21 days prior to registration; patients must have completed any radioimmunotherapy at least 84 days prior to registration; patients must have recovered from all treatment related toxicities from these therapies prior to registrationXx_NEWLINE_xXPatients must not have had prior radiation therapy within 14 days prior to registrationXx_NEWLINE_xX